Partners to Benefit from Green Cloud Financing Boost

Green Cloud Technologies, the channel-only cloud provider, has received the largest investment in its eight-year history from Goldman Sachs Specialty Lending Group (GSSLG).

The financing package supports Green Cloud’s short-term and long-term growth goals to advance the company’s business model focused on building partner networks and providing customers with servers, backup and recovery solutions. The amount of the financing is not being disclosed.

Charles Houser, Green Cloud’s co-founder and executive vice president of sales and marketing, tells Channel Partners the financing will benefit his company’s partners because “this will mean more product expansion and development for a more robust suite of new security offerings.”

Read more.

Sarepta Therapeutics Enters into Long-term Strategic Manufacturing Partnership with Paragon Bioservices, Greatly Enhancing its Commercial Capacity for Future Gene Therapies

— Partnership significantly expands commercial capacity for Sarepta’s micro-dystrophin gene therapy program, as well as bolsters the Company’s clinical and commercial capacity for its other pipeline programs –

Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a commercial-stage biopharmaceutical company focused on the discovery and development of precision genetic medicine to treat rare neuromuscular diseases, announced today that it has entered into a long-term strategic manufacturing partnership with Paragon Bioservices (Paragon), which will provide Sarepta access to additional commercial manufacturing capacity for its micro-dystrophin Duchenne muscular
dystrophy (DMD) gene therapy program, as well as a manufacturing platform for future gene therapy programs, such as Limb-girdle muscular dystrophy (LGMD).

“We are rapidly building a formidable gene therapy engine, the hallmark of which will be the establishment of our Gene Therapy Center of Excellence in Columbus, Ohio. Therefore, it is incumbent upon us to ensure that our ambition is matched with a sophisticated, robust and scalable manufacturing approach that can accelerate a steady stream of gene therapies to treat life-robbing genetic diseases for the near and long-term,” stated Doug Ingram, Sarepta’s president and chief executive officer.

Continue reading